<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="509">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371965</url>
  </required_header>
  <id_info>
    <org_study_id>KILLER</org_study_id>
    <nct_id>NCT04371965</nct_id>
  </id_info>
  <brief_title>Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19</brief_title>
  <acronym>KILLER</acronym>
  <official_title>Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SARS-CoV-2 coronavirus pandemic is responsible for more than 180,000 deaths worldwide and
      20,000 deaths in France. To date, no treatment or vaccine has been successful.
      Povidone-iodine is an antiseptic suitable for use on the skin and mucosa with potent
      virucidal activity, particularly against coronaviruses. It is marketed for oro-nasopharyngeal
      decolonization.

      24 patients with positive nasopharyngeal SARS-CoV-2 carriage will be randomized (1:1) in an
      experimental group (benefiting from povidone iodine decolonization) or a control group.
      Patients in the experimental group will be asked to gargle with a 1% povidone-iodine
      solution, spray their nose with the same antiseptic solution, and finally applied 10%
      povidone-iodine cream in each nostril, all four times a day for five days. Patients will be
      followed for 7 days to evaluate the efficacy and safety of povidone iodine decolonization.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled open label trial, parallel design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day7</measure>
    <time_frame>Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal carriage</measure>
    <time_frame>Day0, Day1, Day3, Day5 and Day7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay between inclusion and negativation of SARS-CoV-2 nasopharyngeal cell cultures</measure>
    <time_frame>Day0, Day1, Day3, Day5 and Day7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid tests at Day0 and Day7</measure>
    <time_frame>Day0 and Day7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction at Day7 using a numerical comfort scale, graduated from 0 (any discomfort) to 10 (maximum possible discomfort)</measure>
    <time_frame>Day7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily presence of clinical signs in favour of COVID-19, including respiratory distress using NYHA scale, chest pain, anosmia, agueusia, tiredness, cough, stiffness, nasal congestion, dysphagia and diarrhea</measure>
    <time_frame>Day0, Day1, Day3, Day5 and Day7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for ward or intensive care hospitalization</measure>
    <time_frame>Day0, Day1, Day3, Day5 and Day7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Decolonization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% Povidone iodine mouthwash (95 mL), gargle, and nasal spray (2,5 mL by nostril), and 10% nasal gel (one drop). All four time a day for five days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Absence of local decolonization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-Iodine</intervention_name>
    <description>Patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days.</description>
    <arm_group_label>Decolonization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (age over 18 yrs) of both sexes

          -  With positive SARS-CoV-2 carriage by RT-PCR

          -  Having given their written consent after having been informed

        Exclusion Criteria

          -  Patient with low viral load (threshold cycle [Ct] &gt; 25 per RT-PCR),

          -  Patient unable to perform oro-nasopharyngeal decolonization

          -  Known hypersensitivity to one of the constituents, particularly to povidone-iodine,

          -  History of dysthyroidism,

          -  Known coagulopathy,

          -  Participation in another clinical trial aimed at reducing viral load in patients with
             SARS-CoV-2,

          -  Pregnant or breastfeeding women, or women of childbearing age without effective
             contraception

          -  Patients not covered by a social security scheme

          -  Patients with enhanced protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier MIMOZ, Professor</last_name>
    <phone>0549444600</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.mimoz@chu-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabrina SEGUIN, CRA</last_name>
    <phone>0549443229</phone>
    <phone_ext>+33</phone_ext>
    <email>sabrina.seguin@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MIMOZ, Professor</last_name>
      <phone>0549444600</phone>
      <phone_ext>+33</phone_ext>
      <email>olivier.mimoz@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sabrina SEGUIN, CRA</last_name>
      <phone>0549443229</phone>
      <phone_ext>+33</phone_ext>
      <email>sabrina.seguin@chu-poitiers.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Povidone Iodine decolonization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

